Nektar Therapeutics Inc. NKTR
$60.35
▲ +0.29% 24H
About
Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States and internationally. Its lead product candidate, rezpegaldesleukin (also…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees63
TickerNKTR
Statistics
Market Cap$1.78B
Revenue (TTM)$55.2M
Net Income-$164.1M
Net Margin-297.1%
EPS$-9.73
P/E-6.12
P/S35.96
P/B3.03
EV/EBITDA-12.05
ROE-53.6%
Dividend Yield—
Price$60.35
Data: Twelve Data · Revenue = mcap / P/S